RxGen and Miragen Therapeutics said this week that they have received a grant from the National Institutes of Health to continue preclinical research on microRNA targeting in cardiovascular disease.
The grant, worth about $720,000, will also be used to support the development of a novel model system of chronic heart failure, according to the companies.